Extensive condylomata acuminata are beyond the capacity of all topical therapies. The area was initially treated by carbon dioxide laser ablation, and residual small foci of infection were subsequently treated with topical 5% imiquimod cream.
The European Heart Rhythm Association provides the first guide to safe and effective use of apixaban, rivaroxaban, and dabigatran. Included are sections on 15 clinical scenarios, from start up schemes to managing dosing error.
For a patient with atrial fibrillation whose risk of ischemic stroke is low, is antiplatelet therapy the right choice? A revised risk calculation formula, based on the original CHADS2 criteria, restratifies low-risk patients to further help identify those who may not require oral anticoagulation.
Post–hoc analysis of data from the ROCKET-AF trial found similar rates of stroke and systemic emboli after treatment interruption for rivaroxaban and warfarin in 2 out of 3 study cohorts. A very different result was found in the third. More, here.
Could the left atrial appendage closure device, known as the Watchman device, become an alternative to oral anticoagulation for selected patients? Here, more on the 2 trials that have introduced the possibility.
Here: how omega-3 fatty acids may help reduce the risk of AF in postcardiac surgery patients; how incident HF can help predict long-term adverse outcomes in patients with AF; and why an old gout drug may help reduce the risk of AF in patients with heart failure.
Among many considerations when ordering or interpreting a stress test are the limitations and adequacy of the stress modality (exercise, vasodilator, ionotrope) as well as the imaging modality used. Here, top-line reminders for primary care practice. More »